title: Weekly low-dose paclitaxel and carboplatin therapy in gynecological cancer patients with venous thrombosis.
abstract: BACKGROUND
  To evaluate the safety and toxicity of weekly low-dose paclitaxel plus carboplatin therapy in gynecological cancer patients with venous thrombosis (VT).
  
  
  METHODS
  Ovarian or endometrial cancer patients with VT who were scheduled to receive neoadjuvant or adjuvant chemotherapy were eligible. Each 21-day cycle of treatment consisted of carboplatin (AUC 2.0) and paclitaxel (80 mg/m2) on days 1, 8 and 15. At the end of chemotherapy, each patient's VT was checked by ultrasonography.
  
  
  RESULTS
  Twenty-five gynecological cancer patients who received warfarin therapy with a target international normalized ratio (INR) of 1.5-2.5 were enrolled in this study. Neutropenia and peripheral neuropathy (grades 3 or 4) occurred in 26% and 4% of the patients, respectively. Chemotherapy did not cause any changes of the INR in any patient. After chemotherapy, the VT showed resolution in 19 patients (76%) and no patient developed fresh thrombosis.
  
  
  CONCLUSIONS
  Weekly low-dose paclitaxel plus carboplatin therapy is a reasonable treatment option for gynecological cancer patients with VT.
authors.affiliation: Department of Obstetrics and Gynecology, Mie University School of Medicine, 2-174, Edobashi, Tsu-City, Mie 514-8507, Japan. tabatat@clin.medic.mie-u.ac.jp
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Tabata
authors.forename: Kouji
authors.initials: K
authors.lastname: Tanida
authors.forename: Takashi
authors.initials: T
authors.lastname: Umekawa
authors.forename: Takaya
authors.initials: T
authors.lastname: Shiozaki
authors.forename: Eiji
authors.initials: E
authors.lastname: Kondo
authors.forename: Kenji
authors.initials: K
authors.lastname: Nagao
authors.forename: Toshiaru
authors.initials: T
authors.lastname: Okugawa
authors.forename: Norimasa
authors.initials: N
authors.lastname: Sagawa
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016190:Carboplatin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D016889:Endometrial Neoplasms / Q000097:blood / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D020246:Venous Thrombosis / Q000150:complications* / Q000188:drug therapy; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D014859:Warfarin; D016190:Carboplatin; D017239:Paclitaxel